

NeurAxon Appoints Thomas Lategan, PhD as Vice President of Regulatory Affairs

WALTHAM, MA, September 16, 2008 – NeurAxon Inc., a developer of next-generation pain therapeutics, today announced the appointment of Thomas Lategan, PhD to the position of Vice President, Regulatory Affairs for the Company. Dr. Lategan was most recently Vice President, Regulatory Affairs of Panacos Pharmaceuticals, Inc., where he was responsible for interactions with the Food and Drug Administration (FDA), establishing regulatory compliance and heading project management for the company's lead drug candidate. Dr. Lategan has over twenty years of experience in pharmaceutical regulatory affairs and project management.

“Tom's proven track record with the FDA, including two FDA Advisory Committee meetings and three drug approvals, as well regulatory strategy and protocol design will be extraordinarily valuable for NeurAxon,” said Lawrence Bloch, MD, JD, CEO of NeurAxon. “We are especially pleased to welcome Tom to the Company at this time as his experience will contribute directly to our current transition from serial to parallel clinical development of our product candidates from our internally generated pipeline for the treatment of serious pain indications.”

“I am excited to join NeurAxon as it enters the next phase of its mission to bring a pipeline of first-in-class therapeutics to patients living with pain,” said Thomas Lategan, PhD, Vice President, Regulatory Affairs of NeurAxon. “The recent results with NXN-188 and migraine with aura illustrate the great potential of nNOS inhibition as a treatment approach for patients suffering with particularly severe migraine.”

Prior to joining Panacos in 2007, Dr. Lategan was Vice President, Regulatory Affairs at Actelion Pharmaceuticals US, Inc., during which time he led the compilation and submission of the approved NDA for Tracleer[®] to the FDA and managed subsequent interactions with the Agency. He also drove approval of Zavesca[®] in the US following its unsuccessful application by a previous sponsor. From 1997 to 2000, Dr. Lategan held the position of Vice President, Regulatory Affairs at the Medicines Company where he was responsible for the successful completion and submission of the NDA for Angiomax[®]. Dr. Lategan also took a lead role in planning and managing several clinical and pre-clinical studies. He held a series of management positions at Hoffman-La Roche and Roche Laboratories from 1988 through 1997. Dr. Lategan holds a Bachelor of Science degree in Pharmacology from the University of Aberdeen and earned his doctorate in Pharmacology from the University of Oxford. He completed a post-doctoral research fellowship at the University of Miami School of Medicine.

About NeurAxon Inc.

NeurAxon Inc. (www.neuraxon.com) is a leader in discovering and developing next-generation pain therapeutics focused on the inhibition of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.

Contact:

Chris Erdman
MacDougall Biomedical Communications
508.647.0209 x14